Strange Signs: Cancer-Related Paraneoplastic Syndromes
November 15, 2019 – Arlene Weintraub
FDA Approves Imfinzi for Locally Advanced Non-Small Cell Lung Cancer
February 17, 2018 – Jason M. Broderick
Longtime Lung Cancer Thrivers
November 18, 2019 – Jeannette Moninger
Currently Viewing
Investigational Drug Shows Promise in Patients with RET-Altered Cancers
November 19, 2019 – Katie Kosko
Lung-MAP Trial Reveals Genetic Testing Knowledge Gaps Among Patients
November 20, 2019 – Katie Kosko
Living with Lung Cancer: The Silver Linings
November 22, 2019 – Samantha Mixon
Everyone Deserves Quality Care in Lung Cancer
November 22, 2019 – Jennifer C. King, Ph.D.
Living After Loss
November 26, 2019 – Katie Kosko
Beyond the Lungs
November 25, 2019 – Deborah Abrams Kaplan
Paraneoplastic Syndromes: A Puzzling Piece of Cancer
November 24, 2019 – Debu Tripathy, M.D.
It's a Great Day to Thrive
November 23, 2019 – Mike Hennessy, Sr.

Investigational Drug Shows Promise in Patients with RET-Altered Cancers

Patients with RET-fusion-positive non-small cell lung cancer (NSCLC) had a high response to LOXO-292 (selpercatinib), according to findings from the largest clinical trial of patients with RET-altered cancers.
BY Katie Kosko
PUBLISHED November 19, 2019
Patients with RET-fusion-positive non-small cell lung cancer (NSCLC) had a high response to LOXO-292 (selpercatinib), according to findings from the largest clinical trial of patients with RET-altered cancers.

The oral investigational medication was examined in 105 patients who had a median of three prior treatment regimens. LOXO-292 showed a 68% objective response rate, meaning their tumors shrunk by at least 30%.

“In this large cohort, selpercatinib’s response rate, durability, robust CNS (central nervous system) activity and safety show promise,” Dr. Alexander Drilon, the lead investigator and a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, said in a press release. “Furthermore, this continues to confirm that RET fusions are clinically targetable alterations, placing them in the company of activating EGFR/ALK/ROS1 alterations.”

RET fusions, rare genetic alterations of NSCLC, occur in roughly 2% of NSCLC cases. Up to 50% of these cancers can spread to the brain.

LOXO-292 was well-tolerated by patients. A safety analysis that included all 531 patients enrolled in the trial showed that nine patients stopped treatment because of a therapy-related side effect. The most common side effects included dry mouth, diarrhea, hypertension, increased liver enzymes, fatigue, constipation and headache.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Lung Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In